Esperion Therapeutics, Inc. ESPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-8.63
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $403.1M | -$22.7M | — | -$13.1M | -$302.0M |
| 2024 | $332.3M | -$51.7M | — | -$24.0M | -$388.7M |
| 2023 | $116.3M | -$209.2M | — | -$135.5M | -$455.0M |
| 2022 | $75.5M | -$233.7M | — | -$174.8M | -$323.8M |
| 2021 | $78.4M | -$269.1M | — | -$263.8M | -$196.9M |
| 2020 | $227.5M | -$143.6M | — | -$86.0M | -$96.1M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -8.63 (distress)
- Working capital / assets 0.347
- Retained earnings / assets -3.485
- EBIT / assets 0.129
- Equity / liabilities -0.393
Source: SEC EDGAR filings · CIK 0001434868 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.